APA

Hicks C. B., Cahn P., Cooper D. A., Walmsley S. L., Katlama C., Clotet B., Lazzarin A., Johnson M. A., Neubacher D., Mayers D. & Valdez H. (20060822). Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. : Lancet (London, England).

Chicago

Hicks Charles B, Cahn Pedro, Cooper David A, Walmsley Sharon L, Katlama Christine, Clotet Bonaventura, Lazzarin Adriano, Johnson Margaret A, Neubacher Dietmar, Mayers Douglas and Valdez Hernan. 20060822. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. : Lancet (London, England).

Harvard

Hicks C. B., Cahn P., Cooper D. A., Walmsley S. L., Katlama C., Clotet B., Lazzarin A., Johnson M. A., Neubacher D., Mayers D. and Valdez H. (20060822). Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. : Lancet (London, England).

MLA

Hicks Charles B, Cahn Pedro, Cooper David A, Walmsley Sharon L, Katlama Christine, Clotet Bonaventura, Lazzarin Adriano, Johnson Margaret A, Neubacher Dietmar, Mayers Douglas and Valdez Hernan. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. : Lancet (London, England). 20060822.